



Cannabinoid CB2 Receptor Agonist

Worldwide Partnering Opportunity



1. Executive Summary : CB2 agonist RQ-00202730

- Mechanism of Action
 - CB2 receptor agonist
- Target Indication
 - Irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)
- Target Product Profile
 - Relieve pain and normalize bowel dysfunction associated with IBS and IBD
 - Anti-inflammatory for IBD by reducing inflammatory cytokines, e.g., TNF α
- Non-clinical Profile for RQ-00202730
 - A specific CB2 agonist with an EC₅₀ = 7.4 nM in a hCB2-CHO cell-based assay
 - » No CB1 activity *in vitro* (EC₅₀ >25 μ M) and *in vivo* (>300 mg/kg, p.o.)
 - Oral activity in animal models of IBS
 - » TNBS-induced visceral hypersensitivity
 - » Stress-induced defecation
 - PK profiles consistent with BID dosing
 - Safety profile *in vitro*
 - » No Genotoxicity (Ames & micronucleus)
 - » No I-hERG inhibition up to 30 μ M
- Patent filed in 2009

2. Table of Contents

Title	Slide No.
1. Executive Summary: CB2 agonist RQ-00202730	2
2. Table of Contents	3
3. Indications for CB2 agonist	4
4. Scientific Rationale	5
5. Mechanism of Action of CB2 agonist	7
6. Unmet Medical Needs and Market	8
7. Compound Attributes	12
7.1. Compound Information	13
7.2. Non-Clinical Pharmacology	14
7.3. Non-Clinical Pharmacokinetics	21
7.4. Non-Clinical Safety	22
7.5. Summary of RQ-00202730	23
8. Competitors	24
9. Appendix	25

弊社とのパートナーリングをご希望の方は「[お問い合わせ](#)」よりご連絡ください

ラクオリア創薬株式会社

Copyright RaQualia Pharma Inc. All Rights Reserved. 2011